Clinical Trials

We are currently evaluating Hu5F9-G4 in five ongoing monotherapy Phase 1 and combination therapy Phase 1b/2 trials, in patients with solid tumors, leukemia or lymphoma.

Monotherapy
Hu5F9-G4
DISCOVERY
PRE-CLINICAL
PHASE 1
DISCOVERY
PRE-CLINICAL
PHASE 1
Tumor Targeting Antibody Combinations
Hu5F9-G4 + Rituximab
Partner
DISCOVERY
PRE-CLINICAL
PHASE 1b
PHASE 2
Hu5F9-G4 + Cetuximab
Partner
CRC
DISCOVERY
PRE-CLINICAL
PHASE 1b
PHASE 2
Immuno-Oncology Agent Combinations
Hu5F9-G4 + undisclosed targets
Partner
Multiple
DISCOVERY
PRE-CLINICAL
Other Combinations
Hu5F9-G4 + Azacitidine
Partner
DISCOVERY
PRE-CLINICAL
PHASE 1b

AML = Acute Myeloid Lymphoma
B-cell NHL = B-cell Non-Hodgkin Lymphoma
CRC = Colorectal Cancer
MDS = Myelodysplastic Syndrome

Planned
Active